US2006128656A1PendingUtilityA1

Charged phospholipid compositions and methods for their use

63
Individually held — no corporate assignee on recordPriority: Jul 31, 2000Filed: Jan 31, 2006Published: Jun 15, 2006
Est. expiryJul 31, 2020(expired)· nominal 20-yr term from priority
Inventors:Daniel Sparks
A61K 31/685A61P 7/02A61P 3/06A61P 31/04A61K 31/66A61K 31/663A61P 39/02A61K 31/683A61P 31/12A61P 9/10A61P 31/22
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of cholesterol and regulate the function of lipolytic enzymes, retard prothrombin formation and aid in the clearance of virus and bacterial particles. Negatively charged lipid compositions can therefore be administered to humans and animals for the treatment of hyperlipidemia and blood coagulation disorders and to reduce the levels of virus, bacteria, and endotoxins in the blood stream. Positively charged lipid compositions can be administered to delay lipoprotein clearance from the plasma compartment and give longer duration of activity for drugs which are associated with lipoproteins.

Claims

exact text as granted — not AI-modified
1 . A method for treating a mammal infected with a pathogen selected from a virus or a bacterium, the method comprising administering to said mammal a therapeutically effective amount of a negatively charged phospholipid for achieving removal of either said pathogen or an endotoxin derived therefrom from the bloodstream of said mammal.  
     
     
         2 . The method of  claim 1 , wherein the mammal is a human.  
     
     
         3 . The method of  claim 1 , wherein said isolated negatively charged phospholipid is phosphatidylinositol, phosphatidylserine, phosphatidylglycerol, or phosphatidic acid, or a mixture thereof.  
     
     
         4 . The method of  claim 1 , wherein said isolated negatively charged phospholipid is phosphatidylinositol.  
     
     
         5 . The method of  claim 1 , wherein said isolated negatively charged phospholipid is phosphatidylserine.  
     
     
         6 . The method of  claim 1 , wherein said isolated negatively charged phospholipid is phosphatidylglycerol.  
     
     
         7 . The method of  claim 1 , wherein said isolated negatively charged phospholipid is phosphatidic acid.  
     
     
         8 . The method of  claim 1 , wherein said isolated negatively charged phospholipid is administered in a dose of 5 micromole to 100 micromole per kg body weight of the mammal.  
     
     
         9 . The method of  claim 1 , wherein said isolated negatively charged phospholipid is administered in a dose of 5 micromole to 20 micromole per kg body weight of the mammal.  
     
     
         10 . The method of  claim 1 , wherein said isolated negatively charged phospholipid is formulated as a food additive.  
     
     
         11 . The method of  claim 1 , wherein said isolated negatively charged phospholipid is formulated as a medicament.  
     
     
         12 . The method of  claim 11 , wherein the medicament is administered orally, intranasally, transdermally, or by injection.  
     
     
         13 . The method of  claim 1 , wherein said isolated negatively charged phospholipid is in the form of unilammellar vesicles, multilamellar vesicles, multilamellar sheets, dispersion, micellar solutions, emulsions, or microemulsions.  
     
     
         14 . The method of  claim 1 , wherein said isolated negatively charged phospholipid is in the form of a powder.  
     
     
         15 . The method of  claim 1 , wherein said pathogen is a virus.  
     
     
         16 . The method of  claim 15 , wherein said virus belongs to the Herpes virus family.  
     
     
         17 . The method of  claim 16 , wherein said virus is cytomegalovirus (CMV).  
     
     
         18 . The method of  claim 1 , wherein said pathogen is a bacterium.  
     
     
         19 . The method of  claim 18  which achieves removal of said endotoxin from the bloodstream.  
     
     
         20 . The method of  claim 19 , wherein said endotoxin is a lipopolysaccharide complex.  
     
     
         21 . A method for treating a mammal infected with a virus, the method comprising administering to said mammal a therapeutically effective amount of phosphatidylinositol for achieving removal of said virus from the bloodstream of said mammal.  
     
     
         22 . The method of  claim 21 , wherein said virus belongs to the Herpes virus family.  
     
     
         23 . The method of  claim 22 , wherein said virus is cytomegalovirus (CMV).  
     
     
         24 . Use of a negatively charged phospholipid in the preparation of a medicament for treating a mammal infected with a pathogen selected from a virus or a bacterium, wherein said medicament comprises a therapeutically effective amount of the isolated negatively charged phospholipid for achieving removal of either said pathogen or an endotoxin derived therefrom from the bloodstream of said mammal.  
     
     
         25 . A pharmaceutical composition for treating a mammal infected with a pathogen selected from a virus or a bacterium, the pharmaceutical composition comprising a therapeutically effective amount of a negatively charged phospholipid for achieving removal of either said pathogen or an endotoxin derived therefrom from the bloodstream of said mammal.

Join the waitlist — get patent alerts

Track US2006128656A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.